Terrassa (Barcelona), 25 February 2026 — FRESCI by SCIENCE&STRATEGY SL today announced the launch of VISI-ON-BRAIN (Cutting-edge Human In Vitro and In Silico Biomedical Tools on Brain Disorders), a Horizon Europe project funded with over €4.5 million under the Marie Skłodowska-Curie Actions – Doctoral Networks (MSCA-DN). Over 48 months (2026–2029) , the consortium will train 15 doctoral researchers to develop and apply next-generation human in vitro and in silico approaches

Transforming scientific discovery into real-world health impact is no longer just a scientific challenge. It is a strategic exercise that demands alignment between evidence, regulation, and innovation pathways. In today’s rapidly evolving scientific landscape, the ability to translate a discovery into a real-world health solution is no longer a purely scientific challenge. It is a strategic one. This is where innovative frameworks and tools come into play, enabling researcher

**Advanced Therapy (ATMP) projects often fail from poor decision-making, not weak science. FRESCI tackles this bottleneck by structuring uncertainty, aligning evidence with strategic goals, and applying proactive regulatory science. Our focus: smarter decisions and clear thinking to navigate ATMP complexity and translate scientific potential into approved, accessible therapies.

In today’s fast-evolving biotech and medtech landscape, businesses face unprecedented challenges. Navigating complex regulatory environments, accelerating technology readiness levels (TRL), and translating scientific discoveries into impactful health solutions require more than traditional approaches. This is where innovative consulting strategies come into play. By integrating evidence-based insights, AI-powered intelligence, and regulatory expertise, companies can transform